stockrow
Saturday 7 November 2026
Export MTNB’s income statement to Excel — free account
Matinas Biopharma Holdings, Inc.
MTNB Healthcare Biotechnology
Matinas Biopharma Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.1 million, down 65.6% from fiscal 2022.
- EPS
- +79.6%
- Free cash flow
- +9.15%
- Total debt
- −54.5%
Quarter to June 2026, against a year earlier
1.19
0.03
+2.59%
Follow MTNB
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(157.24%) | (176.54%) | (241.67%) | (154.28%) | |
| (115.51%) | (110.46%) | (125.39%) | (98.53%) | ||
ROIC |
(876.71%) | (553.44%) | (750.22%) | (419.27%) | |
Return on Tangible Assets |
(405.29%) | (398.65%) | (1,357.68%) | 3,530.92% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(24.57) | (18.33) | (15.46) | (15.02) | |
Free Cash Flow |
(8.91) | (6.69) | (6.60) | (6.42) | |
Capital Expenditures |
0.10 | 0.32 | — | — | |
| Other line items | |||||
Cash ROIC |
(74.52%) | (75.33%) | (120.64%) | (245.41%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.52 | 0.64 | 0.59 | 0.88 | |
Depreciation/Fixed assets |
3.89 | 3.30 | 2.91 | 0.00 | |
Capex/Depreciation |
0.17 | 0.70 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(24.85) | (19.20) | (15.46) | (15.02) | |
Capex per Share |
0.28 | 0.87 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 2 Nov 2026